Cellectar Biosciences Inc. priced its underwritten public offering of common shares and warrants to raise gross proceeds of $14.4 million.

The Madison, Wis.-based company is offering common shares at $4 apiece, accompanied by a five-year series E warrant to purchase 1 common share exercisable at $4 per share.

Cellectar is also offering buyers, who will own more than 4.99% of its outstanding shares, the option to purchase 1,114 series C convertible preferred shares at a public offering price of $10,000 per share and a series E warrant to purchase 2,500 common shares with an exercise price of $4 per share.

The series C preferred shares are convertible into 2,500 common shares at a conversion price of $4.00 per share.

The biopharmaceutical company has granted the underwriters an overallotment option to buy up to an additional 540,000 common shares and warrants to purchase up to 540,000 shares.

The offering is expected to close July 31, subject to customary closing conditions.

Ladenburg Thalmann & Co. Inc. is acting as the book-running manager, while CIM Securities LLC is serving as a co-manager for the offering.